New hope for Tough-to-Treat skin cancer: experimental combo targets resistant melanoma
NCT ID NCT06771544
Summary
This study is testing whether adding a low-dose chemotherapy drug (cyclophosphamide) to an existing immunotherapy (pembrolizumab) can help patients with advanced melanoma that has stopped responding to standard treatments. The trial will enroll 14 adults with stage III or IV melanoma that has progressed despite previous immunotherapy. Researchers will measure whether tumors shrink, track side effects, and monitor how long patients live without their cancer worsening.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Chao Family Comprehensive Cancer Center University of California, Irvine
RECRUITINGOrange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.